Iksuda Therapeutics

Through our highly experienced ADC Research & Development Team, we are building a pipeline of class-leading ADCs with superior therapeutic index (TI) for difficult-to-treat cancers. Our approach is to develop the best ADC for any given target or tumor sub-type rather than technology-driven ADCs. All our ADCs incorporate tumor-selective release & activation of the most relevant payload according to mechanism, optimizing anti-cancer efficacy and enhancing patient safety

Antibody-drug conjugates,permalink™,conjugation chemistry,cancer research,adcs,drug development,therapeutics,antibodies,toxins,cancer treatment,adc stability,antibody drug conjugate,drug discovery,biotechnology,preclinical,bioconjugation,organic synthesis,clinical,cell biology,chemistry,and licencing

Iksuda therapeutics operates in the Biotechnology research industry.

Iksuda therapeutics's revenue is 11m - 100m

Iksuda therapeutics has 11 - 50 employees.